Pilot study of vitaxin—an angiogenesis inhibitor—in patients with advanced leiomyosarcomas
✍ Scribed by Shreyaskumar R. Patel; Jan Jenkins R.N.; Nicholas Papadopolous; M. Andrew Burgess; Carl Plager; Jordan Gutterman; Robert S. Benjamin
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 41 KB
- Volume
- 92
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## Background. Intraoperative manipulation of the tumor during cancer surgery has long been recognized as a source of metastasis and contamination of the surgical wound during tumor removal. We explored the use of intraoperative chemotherapy to minimize the risk of tumor cell implantat
## Abstract ## BACKGROUND. The objective of this study was to determine whether hypogonadism and autonomic dysfunction contribute substantially to cancer‐related fatigue, decreased sexual desire, and depression in male patients with advanced, incurable cancer. ## METHODS. Forty‐eight patients wh
## Abstract ## BACKGROUND OSI‐211 is a low‐clearance, unilamellar liposomal formulation of a water‐soluble camptothecin analogue, lurtotecan. OSI‐211 has significant activity in severe combined immunodeficient mouse models of human leukemia. ## METHODS This study was conducted to define the dose
## Background: Head and neck squamous cell carcinomas (hnsccs) were previously shown to express a repertoire of cytokines and angiogenesis factors that contribute to malignant pathogenesis and are detectable in serum. pretreatment and posttreatment serum levels of cytokines and angiogenesis factors